R.W. Johnson Mylinax
Executive Summary
FDA cancels Jan. 29 meeting of the Peripheral & Central Nervous System Drugs Advisory Committee. The committee was scheduled to review Mylinax (cladribine) for treatment of multiple sclerosis
You may also be interested in...
Ivax/Serono Oral MS Therapy Mylinax Efficacy Trials Planned For 2004
Ivax and Serono hope to launch pivotal trials for their oral multiple sclerosis therapy Mylinax (cladribine) in late 2004
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011